Compare
Allarity Therapeutics, Inc. vs ProPhase Labs, Inc. vs Roivant Sciences Ltd. vs Tonix Pharmaceuticals Holding Corp.
| Latest fiscal year | Allarity Therapeutics, Inc. ALLR | ProPhase Labs, Inc. PRPH | Roivant Sciences Ltd. ROIV | Tonix Pharmaceuticals Holding Corp. TNXP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-03-31 | 2025-12-31 |
| Revenue | $320.0K | $4.34M | $8.26M | $13.11M |
| Revenue growth (YoY) | n/a | -35.8% | -71.6% | +29.8% |
| Gross margin | n/a | 31.9% | n/a | 49.3% (computed) |
| Operating margin | n/m | -415.4% | n/m | -959.1% |
| Net margin | n/m | -339.3% | n/m | -946.2% |
| Net income | -$11.23M | -$14.74M | -$299.77M | -$124.02M |
| EPS (Diluted) | n/a | -$1.74 | -$0.54 | -$14.57 |
| Operating cash flow | -$14.82M | -$8.34M | -$750.35M | -$99.84M |
| Free cash flow | -$14.83M | -$8.34M | -$758.56M | -$103.21M |
| Cash & equivalents | $14.69M | $90.0K | $1.42B | $207.64M |
| Total assets | $18.26M | $59.87M | $5.71B | $277.17M |
| Total liabilities | $8.43M | $56.36M | $416.27M | $32.02M |
| Shareholders' equity | $9.83M | $3.51M | $4.53B | $245.15M |
| Return on year-end equity | -114.3% | -420.3% | -6.6% | -50.6% |
| Shares outstanding | 16.08M | 8.97M | 720.35M | 12.79M |
Revenue, most recent five fiscal years
| Fiscal year | Allarity Therapeutics, Inc. | ProPhase Labs, Inc. | Roivant Sciences Ltd. | Tonix Pharmaceuticals Holding Corp. |
|---|---|---|---|---|
| Latest | $320.0K Ended 2025-12-31 | $4.34M Ended 2025-12-31 | $8.26M Ended 2026-03-31 | $13.11M Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2024-12-31 | $6.77M Ended 2024-12-31 | $29.05M Ended 2025-03-31 | $10.09M Ended 2024-12-31 |
| 2 years earlier | n/a | $34.98M Ended 2023-12-31 | $32.71M Ended 2024-03-31 | $7.77M Ended 2023-12-31 |
| 3 years earlier | n/a | $122.65M Ended 2022-12-31 | $31.53M Ended 2023-03-31 | n/a |
| 4 years earlier | n/a | $79.04M Ended 2021-12-31 | $55.29M Ended 2022-03-31 | n/a |